Articles with public access mandates - Gunasingh MasilamoniLearn more
Not available anywhere: 4
Glucose oxidase incorporated collagen matrices for dermal wound repair in diabetic rat models: a biochemical study
V Arul, JG Masilamoni, EP Jesudason, PJ Jaji, M Inayathullah, ...
Journal of biomaterials applications 26 (8), 917-938, 2012
Mandates: Council of Scientific and Industrial Research, India
Group I metabotropic glutamate receptors in the primate motor thalamus: subsynaptic association with cortical and sub-cortical glutamatergic afferents
GJ Masilamoni, Y Smith
Brain Structure and Function 224, 2787-2804, 2019
Mandates: US National Institutes of Health
Neuroprotective Properties of Glutamate Metabotropic Glutamate Receptors in Parkinson’s Disease and Other Brain Disorders
GJ Masilamoni, Y Smith
mGLU Receptors, 103-127, 2017
Mandates: US National Institutes of Health
Role of Protein Aggregation and Interactions between α-Synuclein and Calbindin in Parkinson’s Disease
MM Gromiha, S Biswal, AM Thangakani, S Kumar, GJ Masilamoni, ...
Intelligent Computing Theories and Technology: 9th International Conference …, 2013
Mandates: Department of Biotechnology, India
Available somewhere: 15
Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys
GJ Masilamoni, JW Bogenpohl, D Alagille, K Delevich, G Tamagnan, ...
Brain 134 (7), 2057-2073, 2011
Mandates: US National Institutes of Health
Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson’s disease
GJ Masilamoni, Y Smith
Journal of Neural Transmission 125, 337-363, 2018
Mandates: US National Institutes of Health
Microglia, inflammation and gut microbiota responses in a progressive monkey model of Parkinson's disease: A case series
V Joers, G Masilamoni, D Kempf, AR Weiss, TM Rotterman, B Murray, ...
Neurobiology of disease 144, 105027, 2020
Mandates: US National Institutes of Health, Michael J Fox Foundation, Parkinson's …
18F-FECNT: Validation as PET dopamine transporter ligand in parkinsonism
G Masilamoni, J Votaw, L Howell, RM Villalba, M Goodman, RJ Voll, ...
Experimental neurology 226 (2), 265-273, 2010
Mandates: US National Institutes of Health
Metabotropic glutamate receptors: targets for neuroprotective therapies in Parkinson disease
GJ Masilamoni, Y Smith
Current opinion in pharmacology 38, 72-80, 2018
Mandates: US National Institutes of Health
Extrastriatal D2-like receptors modulate basal ganglia pathways in normal and Parkinsonian monkeys
A Hadipour-Niktarash, KS Rommelfanger, GJ Masilamoni, Y Smith, ...
Journal of neurophysiology 107 (5), 1500-1512, 2012
Mandates: US National Institutes of Health
Reduced noradrenergic innervation of ventral midbrain dopaminergic cell groups and the subthalamic nucleus in MPTP-treated parkinsonian monkeys
GJ Masilamoni, O Groover, Y Smith
Neurobiology of disease 100, 9-18, 2017
Mandates: US National Institutes of Health, Parkinson's Foundation, USA
Proteomic profiling in MPTP monkey model for early Parkinson disease biomarker discovery
X Lin, M Shi, JG Masilamoni, R Dator, J Movius, P Aro, Y Smith, J Zhang
Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics 1854 (7), 779-787, 2015
Mandates: US National Institutes of Health, National Natural Science Foundation of China
Phosphodiesterase 10A inhibitor MP-10 effects in primates: comparison with risperidone and mechanistic implications
S Uthayathas, GJ Masilamoni, CL Shaffer, CJ Schmidt, FS Menniti, ...
Neuropharmacology 77, 257-267, 2014
Mandates: US National Institutes of Health
Cortical serotonergic and catecholaminergic denervation in MPTP-treated parkinsonian monkeys
GJ Masilamoni, A Weinkle, SM Papa, Y Smith
Cerebral cortex 32 (9), 1804-1822, 2022
Mandates: US National Institutes of Health
Lack of antiparkinsonian effects of systemic injections of the specific T-type calcium channel blocker ML218 in MPTP-treated monkeys
A Galvan, A Devergnas, D Pittard, G Masilamoni, J Vuong, JS Daniels, ...
ACS chemical neuroscience 7 (11), 1543-1551, 2016
Mandates: US National Institutes of Health
Effects of a novel phosphodiesterase 10A inhibitor in non-human primates: A therapeutic approach for schizophrenia with improved side effect profile
GJ Masilamoni, S Uthayathas, G Koenig, L Leventhal, SM Papa
Neuropharmacology 110, 449-457, 2016
Mandates: US National Institutes of Health
Dysfunction of motor cortices in Parkinson’s disease
HY Chu, Y Smith, WW Lytton, S Grafton, R Villalba, G Masilamoni, ...
Cerebral Cortex 34 (7), bhae294, 2024
Mandates: Michael J Fox Foundation, Aligning Science Across Parksinson's, USA
Phosphodiesterase 9 inhibition prolongs the antiparkinsonian action of l-DOPA in parkinsonian non-human primates
GJ Masilamoni, CG Sinon, BA Kochoian, A Singh, AJ McRiner, ...
Neuropharmacology 212, 109060, 2022
Mandates: US National Institutes of Health
Sexually dimorphic responses to MPTP found in microglia, inflammation and gut microbiota in a progressive monkey model of Parkinson’s disease
V Joers, G Masilamoni, D Kempf, AR Weiss, T Rotterman, B Murray, ...
bioRxiv, 2020.01. 30.925883, 2020
Mandates: US National Institutes of Health, Parkinson's Foundation, USA
Publication and funding information is determined automatically by a computer program